SEC Form 4	
FORM 4	UNITED STATES SECU

JRITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	_
OMB APPROVAL	

3235-0287

OMB Number:

Check this box if Section 16. Form obligations may o Instruction 1(b).		S		ed purs	OF CHANC suant to Section 1 Section 30(h) of t	6(a) of t	he Se	curities Exchar	nge Act o	of 1934	SHIP	OMB Number: Estimated average hours per response		
1. Name and Address of Reporting Person [*] Nijhawan Pardeep					suer Name and T esa Biotech,					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner				
(Last) C/O EDESA BIO 100 SPY COUR		(Middle)	1	3. Date of Earliest Transaction (Month/Day/Year) 11/02/2022							- X Officer (give title Other (specify below) below) Chief Executive Officer			
(Street) MARKHAM (City)	A6 (State)	L3R 5: (Zip)			Amendment, Date					Lir	X Form filed b Person	Group Filing (Cheo y One Reporting y More than One	Person	
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
						Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Shares			11/02/202	22		А		228,262	A	\$1.125 ⁽¹⁾	2,356,914	I	Held by Pardeep Nijhawan Medicine Professional Corporation ⁽²⁾	
Common Shares			11/02/202	22		A		228,262	A	\$1.125(1)	228,262	I	By Trust	
Common Shares											594,812	D		
Common Shares											224,094	I	Held by The Digestive Health Clinic Inc. ⁽²⁾	
Common Shares											371,727	I	Held by 1968160 Ontario Inc. ⁽²⁾	
		Table			Securities Ac						Owned		•	

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A or Dispose of (D) (Instr. 3, 4 and 5)		e s I (A) sed str.	6. Date Exerc Expiration Da (Month/Day/Y	ite	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Common Share Warrants (Right to Buy) ⁽³⁾	\$1.5	11/02/2022		A		114,131		(3)	(3)	Common Shares	114,131	(1)	114,131	I	Held by Pardeep Nijhawan Medicine Professional Corporation ⁽²⁾
Common Share Warrants (Right to Buy) ⁽³⁾	\$1.5	11/02/2022		А		114,131		(3)	(3)	Common Share	114,131	(1)	114,131	I	By Trust
Common Share Warrants (Right to Buy) ⁽⁴⁾	\$1	11/02/2022		A		114,131		(4)	(4)	Common Shares	114,131	(1)	114,131	I	Held by Pardeep Nijhawan Medicine Professional Corporation ⁽²⁾
Common Share Warrants (Right to Buy) ⁽⁴⁾	\$1	11/02/2022		А		114,131		(4)	(4)	Common Share	114,131	(1)	114,131	I	By Trust
	nd Address of van Parde	Reporting Person [*]													
(Last)		(First)	(Middle)												

C/O EDESA BIOTECH INC.

A6	L3R 5H6
1	
OTECH INC.	
(First)	(Middle)
	Professional Corp
ss of Reporting Persor	,* 1
(State)	(Zip)
A6	L3R 5H6
	(State) ss of Reporting Persor awan Medicine (First) DTECH INC. T

Explanation of Responses:

1. The reported securities are included within 228,262 Common Shares purchased by the reporting person for \$1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share.

2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Pardeep Nijhawan.

3. Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date.

4. Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date.

/s/ Pardeep Nijhawan11/04/2022/s/ Pardeep Nijhawan MedicineProfessional Corporation, byPardeep Nijhawan

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.